Shi Guoli, Kenney Adam D, Kudryashova Elena, Zhang Lizhi, Hall-Stoodley Luanne, Robinson Richard T, Kudryashov Dmitri S, Compton Alex A, Yount Jacob S
bioRxiv. 2020 Aug 11:2020.08.11.246678. doi: 10.1101/2020.08.11.246678.
Interferon-induced transmembrane proteins (IFITMs) restrict infections by many viruses, but a subset of IFITMs enhance infections by specific coronaviruses through currently unknown mechanisms. Here we show that SARS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-2 infections are generally restricted by expression of human IFITM1, IFITM2, and IFITM3, using both gain- and loss-of-function approaches. Mechanistically, restriction of SARS-CoV-2 occurred independently of IFITM3 -palmitoylation sites, indicating a restrictive capacity that is distinct from reported inhibition of other viruses. In contrast, the IFITM3 amphipathic helix and its amphipathic properties were required for virus restriction. Mutation of residues within the human IFITM3 endocytosis-promoting YxxΦ motif converted human IFITM3 into an enhancer of SARS-CoV-2 infection, and cell-to-cell fusion assays confirmed the ability of endocytic mutants to enhance Spike-mediated fusion with the plasma membrane. Overexpression of TMPRSS2, which reportedly increases plasma membrane fusion versus endosome fusion of SARS-CoV-2, attenuated IFITM3 restriction and converted amphipathic helix mutants into strong enhancers of infection. In sum, these data uncover new pro- and anti-viral mechanisms of IFITM3, with clear distinctions drawn between enhancement of viral infection at the plasma membrane and amphipathicity-based mechanisms used for endosomal virus restriction. Indeed, the net effect of IFITM3 on SARS-CoV-2 infections may be a result of these opposing activities, suggesting that shifts in the balance of these activities could be coopted by viruses to escape this important first line innate defense mechanism.
干扰素诱导跨膜蛋白(IFITMs)可限制多种病毒的感染,但有一部分IFITMs却通过目前未知的机制增强特定冠状病毒的感染。在这里,我们使用功能获得和功能缺失方法表明,人IFITM1、IFITM2和IFITM3的表达通常会限制严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白假型病毒和真正的SARS-CoV-2感染。从机制上讲,SARS-CoV-2的限制独立于IFITM3的棕榈酰化位点,这表明其具有与报道的对其他病毒的抑制作用不同的限制能力。相比之下,病毒限制需要IFITM3两亲性螺旋及其两亲性特性。人IFITM3促进内吞作用的YxxΦ基序内的残基发生突变,会将人IFITM3转变为SARS-CoV-2感染的增强子,细胞间融合试验证实了内吞突变体增强刺突蛋白介导的与质膜融合的能力。据报道,跨膜丝氨酸蛋白酶2(TMPRSS2)的过表达可增加SARS-CoV-2的质膜融合而非内体融合,减弱了IFITM3的限制作用,并将两亲性螺旋突变体转变为强大的感染增强子。总之,这些数据揭示了IFITM3新的抗病毒和促病毒机制,在质膜上病毒感染的增强与用于内体病毒限制的基于两亲性的机制之间有明显区别。实际上,IFITM3对SARS-CoV-2感染的净效应可能是这些相反活动的结果,这表明病毒可能会利用这些活动平衡的变化来逃避这一重要的一线先天防御机制。